Aydah AlAwadhi, Consultant Medical Oncologist and Division Chair of Hematology and Oncology Department at Sheikh Shakbout Medical City, shared on LinkedIn:
“ASCENT-03 vs TROPION-Breast02: Two important phase III trials reshaping the first-line treatment landscape of advanced first line immunotherapy-ineligible metastatic TNBC.
I put together this side-by-side comparison highlighting key differences in trial design, patient populations, efficacy, and safety.
Off note: Cross-trial comparisons should be interpreted with caution. No head-to-head evidence yet!
Which ADC would you favor in your clinical practice, and what factors would drive your choice?”
You might be interested in:
TROPION-Breast02: Datopotamab Deruxtecan Preserves Quality of Life in First-Line Metastatic TNBC
